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Abstract
Background: Sterile syringe access is a critical component of HIV prevention programs. Although retail pharmacies
provide convenient outlets for syringe access, injection drug users (IDUs) may encounter barriers to syringe
purchase even where purchase without a prescription is legal. We sought to obtain an objective measure of
syringe access in Tijuana, Mexico, where IDUs report being denied or overcharged for syringes at pharmacies.
Methods: Trained “mystery shoppers” attempted to buy a 1 cc insulin syringe according to a predetermined script
at all retail pharmacies in three Tijuana neighborhoods. The same pharmacies were surveyed by telephone
regarding their syringe sales policies. Data on purchase attempts were analyzed using basic statistics to obtain an
objective measure of syringe access and compared with data on stated sales policies to ascertain consistency.
Results: Only 46 (28.4%) of 162 syringe purchase attempts were successful. Leading reasons for unsuccessful
attempts were being told that the pharmacy didn’t sell syringes (35.3%), there were no syringes in stock (31.0%), or
a prescription was required (20.7%). Of 136 pharmacies also surveyed by telephone, a majority (88.2%) reported
selling syringes but only one-third (32.5%) had a successful mystery shopper purchase; the majority of unsuccessful
purchases were attributed to being told the pharmacy didn’t sell syringes. There was similar discordance regarding
prescription policies: 74 pharmacies said in the telephone survey that they did not require a prescription for
syringes, yet 10 of these pharmacies asked the mystery shopper for a prescription.
Conclusions: IDUs in Tijuana have limited access to syringes through retail pharmacies and policies and practices
regarding syringe sales are inconsistent. Reasons for these restrictive and inconsistent practices must be identified
and addressed to expand syringe access, reduce syringe sharing and prevent HIV transmission.
Background
Injection drug users (IDUs) are at high risk of infection
with HIV, hepatitis C (HCV) and other blood-borne
pathogens transmitted by sharing syringes and other
injection equipment. Globally, almost 20% of the world’s
15.9 million IDUs are infected with HIV [1] and in some
studies HCV prevalence among IDUs is >90% [2].
Transmission of these pathogens can be prevented by
eliminating syringe sharing among IDUs. This requires
that sterile syringes be available at appropriate times and
in sufficient quantities to supply a sterile syringe for each
injection. In most settings, IDUs’ avenues for obtaining
sterile syringes are limited to syringe exchange programs
(SEPs) and pharmacies. SEPs have proven effective in
reducing syringe sharing [3], but the number of these
programs - and the overall number of syringes they dis-
tribute - is not sufficient to provide IDUs with a sterile
syringe for each injection. In Latin America, for example,
only 5 of 20 countries are known to have implemented
SEPs, which serve only approximately 2% of the region’s
IDUs [4].
Pharmacies can provide a more comprehensive and con-
venient source of syringes for IDUs, as they generally
exceed SEPs in number of locations and hours of operation.
In some areas, however, pharmacy-based syringe access is
hampered by laws requiring a prescription for purchase.
Allowing purchase without a prescription has been shown
to increase the number of syringes sold and reduce sharing
among IDUs. In the United States, for example, where syr-
inge access laws vary by state, Connecticut and Minnesota
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saw substantial increases in the number of IDUs who
reported pharmacy purchase of syringes and decreases in
syringe sharing following repeal of syringe prescription laws
[5,6]. Similarly, in New York City, an Expanded Syringe
Access Demonstration Program (ESAP) was associated
with a significant increase in the proportion of IDUs who
obtained syringes from pharmacies, and these IDUs were
less likely than others to report syringe sharing [7].
Unfortunately, even where the “laws on the books”
allow syringe purchase without a prescription, IDUs still
encounter barriers to purchase. U.S.-based studies have
obtained objective measures of IDUs’ ability to purchase
syringes using the “mystery shopper” method, in which
study personnel enter pharmacies and attempt to pur-
chase a sterile syringe according to a predetermined
script. These studies have documented refusal rates of
31-59% in areas where syringe purchase without a pre-
scription is legal [8-12].
In Mexico, where syringe purchase without a prescrip-
tion is also legal, IDUs report being refused or over-
charged for syringes at retail pharmacies and link these
refusals directly with syringe sharing [13,14]. In Tijuana,
a northwestern Mexico border city adjacent to San
Diego, California, 59% of IDUs report receptive syringe
sharing in the past 6 months and HCV prevalence is
96% [15,16]. HIV prevalence among Tijuana’s male
IDUs, female IDUs and female IDUs who engage in sex
work is 4%, 10%, and 12%, respectively [17,18] and as
many as one in 125 persons aged 15-49 in the city are
estimated to be HIV-positive [19]. We undertook
this study to obtain an objective measure of barriers to
pharmacy-based syringe purchase among IDUs in




Tijuana, Mexico has a population of 1.6 million [20] and
is situated on a major illicit drug trafficking route that
brings heroin, methamphetamine and other illicit drugs
northward into the United States [21]. Drugs that do not
make it over the U.S. border are sold plentifully and
cheaply in Tijuana [22,23] which is the site of a growing
drug using population; lifetime illicit drug use prevalence
in Baja California, the state where Tijuana is located, is
9.3% compared to a national prevalence of 5.2% [24], and
there are an estimated 10,000 IDUs in the city [25].
Tijuana is also home to a thriving cross-border market
for legal pharmaceuticals, which are sought by U.S.
consumers for their relatively cheap prices. As a result,
pharmacies are ubiquitous in Tijuana and are particularly
concentrated near the U.S. border, where multiple phar-
macies commonly exist on the same city block.
Human subjects
The study protocol was reviewed and approved by the
Ethics Board of the Tijuana General Hospital and the
Human Research Protections Program of the University of
California, San Diego. A waiver of consent for pharmacy
personnel was granted on the grounds that the protocol
met the requirements of 45 CFR 46.116(d); the research
was determined to be of minimal risk to participants (e.g.,
involvement was limited to normal sales activities, no per-
sonally identifiable information was collected), the waiver
would not adversely affect the subjects’ rights or welfare,
and the research could not practicably be carried out with-
out the waiver. Further, our primary Mexican collaborator
(R.L.) assured that study findings would be presented to
state and local health departments and the local pharmacy
association for dissemination to Tijuana pharmacies after
completion of the study.
Data collection
Mystery shopper syringe purchases
Between April 2006 and April 2007, data on locations of
injection drug use were collected at baseline from parti-
cipants in Proyecto El Cuete, a longitudinal study of
1,056 IDUs in Tijuana. Based on these data, we identi-
fied three colonias (neighborhoods) as the most com-
mon areas of injection drug use in Tijuana: Zona Norte,
Zona Centro and Zona Rio, all of which are located
near the U.S. border and cover an area of approximately
2.6 square miles. Using a list of registered pharmacies
provided by the health department of Baja California
and street maps from Proyecto El Cuete as a guide, our
study staff went street-by-street to create a validated list
of all retail pharmacies in these three colonias.
During August and September, 2009, each pharmacy
was randomly assigned to one of four “mystery shoppers,”
i.e., two male and two female study staff wearing casual
dress common to IDUs. Mystery shoppers were trained to
enter their assigned pharmacies and attempt to purchase a
single 1 cc insulin syringe according to a predetermined
script, which insured uniformity across purchases. Shop-
pers were instructed to pay ≤ 10 pesos per syringe, which
was the median price of syringes purchased at retail phar-
macies based on self-reported baseline data from Proyecto
El Cuete, and not to negotiate with pharmacy staff during
the purchase attempt. They were also instructed not to
disclose their identity or the purpose of their visit to phar-
macy staff at the time of the purchase attempt. Syringe
purchases were attempted between the hours of 8:00 am
and 6:00 pm and were conducted both on weekdays and
weekends.
In all cases, the mystery shopper was driven to the
target pharmacy in a car with a driver and second study
staffer who waited nearby during the purchase attempt.
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After leaving the pharmacy the mystery shopper imme-
diately returned to the car and was debriefed there by
the second study staffer, who recorded information from
the purchase attempt on a data collection form. This
allowed us to immediately record the details and out-
come of the syringe purchase attempt without requiring
that data be recorded inside the pharmacy, thus protect-
ing the nature and purpose of the purchase attempt
from immediate disclosure to pharmacy staff. Data col-
lected included the date and time of the attempt; num-
ber of other shoppers in the store; characteristics of the
staff person from whom the syringe was requested (e.g.,
sex, approximate age); syringe price; whether the pur-
chase was successful; and any additional details the
shopper could provide regarding their interaction with
pharmacy staff. Information from the paper data collec-
tion form was subsequently entered into a database
using Microsoft Excel.
Telephone survey
Between September 2009 and February 2010, the same
pharmacies were contacted by telephone by a female pro-
ject staffer. The person who answered the phone was
asked whether they sold 1 cc insulin syringes and, if so,
how much they cost and whether a prescription was
required for purchase. These data were recorded on a
standardized form and entered into the same Excel data-
base for analysis. Although the telephone survey was con-
ducted after the mystery shopper visits were completed,
the mystery shopper study and its results had not yet been
shared with health departments, pharmacy associations or
pharmacy staff; therefore, the risk of the telephone survey
responses being influenced by knowledge of the mystery
shopper data collection was minimal.
Data analysis
Data from mystery shopper purchase attempts were tabu-
lated to determine the percentage of successful syringe
purchases and reasons for failed purchases. We also iden-
tified factors associated with purchase outcome by com-
paring the characteristics of successful versus unsuccessful
purchase attempts using Wilcoxon rank-sum tests for con-
tinuous variables and the Pearson’s chi-square test for
categorical variables. Data from the telephone survey were
similarly tabulated to determine the percentage of phar-
macies that reported selling syringes and the percentage
that required a prescription for purchase. These results
were then compared with data from the mystery shopper
purchase attempts to identify discrepant findings.
Results
Overall we identified 189 retail pharmacies in the three
targeted colonias and completed purchase attempts at
164 of them. The other 25 pharmacies were excluded
because either the pharmacy had closed since the vali-
dated list was completed (n = 17) or it was determined
not to be an eligible retail pharmacy at the time of the
purchase attempt (n = 8; e.g., sold botanicals only,
pediatric medications only). Of the 164 purchase
attempts, one was excluded because the mystery shop-
per varied from the predetermined script and one was
excluded due to missing data, leaving a total of 162
eligible purchase attempts included in our analysis.
Mystery shopper syringe purchases
Only 46 (28.4%) of the 162 eligible mystery shopper
purchase attempts were successful. The median price
per syringe purchased was 7 pesos (IQR: 5-10). Table 1
compares the characteristics of successful and unsuc-
cessful purchase attempts. There were no statistically
significant differences between the pharmacies where
syringes were successfully purchased and those where
the purchase attempt was unsuccessful; however, female
mystery shoppers were more likely to have a successful
purchase outcome than male shoppers, with marginal
significance (p = 0.058).
Figure 1 presents the reasons for unsuccessful purchase
attempts. One-third (35.3%) of the pharmacies told the
mystery shopper they did not sell syringes and another
one-third (31.0%) said they had no syringes in stock. The
remaining purchase attempts failed either because the
pharmacy requested a prescription (20.7%), charged
more than the maximum established price of 10 pesos
(3.5%; price range 12-15 pesos), referred the mystery
shopper to another pharmacy (2.5%), or for some other
reason (7.0%; e.g., told that syringes were only sold in
packages of 10, only sold 10 cc syringes).
In some cases, the mystery shoppers provided addi-
tional comments regarding their experiences during the
syringe purchase attempt. In five cases, the shopper
noted that although their purchase attempt was unsuc-
cessful the person who waited on them treated them
kindly, as if this experience were out of the ordinary. In
two cases in which the purchase attempt was successful,
the shopper noted that the seller told them to “take
care” or “be careful.” There were two cases in which the
shopper specifically reported that the person who
waited on them was angry or upset, and two others
where they reported being actively observed (e.g.,
“[They] looked at me from head to toe, studied me
[before they said] ‘I can’t sell it to you without a pre-
scription.’”). In three other failed attempts the shopper
reported being completely ignored by the pharmacy
staff (e.g., “[They] continued watching television, didn’t
even look at me.”).
In six cases, the mystery shopper reported lack of
knowledge about the pharmacy policy regarding syringe
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sales or that pharmacy staff disagreed about whether to
sell them the syringe. These interactions were described
as follows:
• “He/she was going to sell it to me but a voice from
behind the wall told him/her that I needed a
prescription.”
• “The guy was going to help me but they girl said
they had run out...she was shaking her head at the
guy as if to say ‘No, don’t sell.’”
• “One (the one that was selling) said yes, but then
asked the boss who said they didn’t have any.”
• “The lady was going to sell to me, the man wasn’t.
‘We don’t have syringes because we don’t have a
fridge for the insulin.’”
• “He/she had to call a supervisor by radio to ask if
he/she could sell it to me or not. [The supervisor
said]...not without a prescription.”
• “One said that with a prescription and the other
one said that there was no problem. In the end it
was sold.”
Telephone survey
Overall, 136 (84.0%) of the 162 pharmacies also com-
pleted the telephone survey; of the 26 pharmacies who
did not complete the survey, a majority (73.1%) could not
be contacted because they did not have a listed phone
number or the phone number was incorrect or out of
service. Only one pharmacy refused to answer questions.
More pharmacies that completed the telephone survey
had a successful mystery shopper purchase attempt than
those that did not complete the survey (30.9% vs. 15.4%)
but the difference was not statistically significant (p =
0.11). The median reported price per syringe was 6 pesos
(IQR: 5-9 pesos), slightly lower than the median price of
7 pesos charged to the mystery shoppers.
A comparison of the telephone survey and mystery
shopper outcomes is provided in Table 2. Overall, 120
(88.2%) of the 136 pharmacies surveyed reported selling
syringes. Of these 120 pharmacies, 32.5% had a success-
ful mystery shopper outcome and 67.5% an unsuccessful
outcome. In the latter cases where pharmacies reported
selling syringes but did not sell one to the mystery shop-
per, the most common reason for the failed purchase
attempt was being told that the pharmacy did not sell
syringes (38.3%). Conversely, there were three pharma-
cies that reported not selling syringes in the telephone
survey but sold a syringe to the mystery shopper.
There was also a high level of discordance regarding
prescription requirements, as shown in Table 2. Overall,
Table 1 Characteristics of successful and unsuccessful retail pharmacy syringe purchase attempts (N = 162)
Successful (%) N = 46 Unsuccessful (%) N = 116 P-value
Mystery shopper sex
Male 19 (41.3) 67 (58.7) .058
Female 27 (58.7) 49 (42.2)
Median number of pharmacy staff who waited on mystery shopper (IQR) 1 (1-2) 1 (1-2) .406
Sex of staff person 1
Male 23 (50.0) 54 (47.0) .727
Female 23 (50.0) 61 (53.0)
Approximate age of staff person 1 31 (25-45) 35 (27-44) .260
Sex of staff person 2
Male 7 (46.7) 11 (40.7) .710
Female 8 (53.3) 16 (59.3)
Approximate age of staff person 2 40 (30-55) 31 (25-44) .109
Median number of customers within 10 feet of shopper 1(0-2) 0 (0-1) .154
Number of customers in store
< 5 43 (97.7) 113 (98.3) .825
5-10 1 (2.3) 2 (1.7)



































Figure 1 Reasons for unsuccessful syringe purchase attempts
(N = 116).
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35 pharmacies (32.1%) said in the telephone survey that
they require a prescription for syringe purchase even
though Mexican law does not require it; however, 13 of
these pharmacies sold a syringe to the mystery shopper
without a prescription. Seventy-four pharmacies (61.7%)
said they did not require a prescription for syringe pur-
chase but 10 of these pharmacies refused the mystery
shopper purchase due to lack of a prescription. The
remaining 11 pharmacies surveyed did not give a defini-
tive answer regarding whether they required a prescrip-
tion for syringe purchases, with seven stating (without
being prompted by the caller) that their decision to ask
a customer for a prescription depended on what the
customer looked like. None of these 11 pharmacies
asked the mystery shopper for a prescription and 5 had
successful mystery shopper purchases.
Discussion
To our knowledge, this is the first published mystery
shopper study of syringe access conducted in a develop-
ing country and the first anywhere to compare mystery
shopper outcomes with a concurrent telephone survey.
We documented a very low level of success in purchasing
sterile syringes at retail pharmacies in Tijuana, Mexico,
and a high level of discordance between stated pharmacy
syringe sales policies and those experienced by the
mystery shoppers.
The low mystery shopper success rate in this study cor-
roborates IDU reports of substantial barriers to phar-
macy-based syringe purchase in Tijuana. In qualitative
studies, IDUs have linked these barriers directly to risky
injection practices, including syringe sharing and scaven-
ging through medical and household waste for used syr-
inges [13,14]. A quantitative study of IDUs in Proyecto El
Cuete similarly demonstrated an independent association
between experiencing barriers to pharmacy-based syringe
purchase and receptive syringe sharing, syringe reuse,
and a higher number of lifetime abscesses [14]. In light of
the mounting evidence regarding restrictive syringe sales
practices in Tijuana and their direct contribution to risky
injection behaviors, structural interventions are needed
to modify these sales practices.
This study provides preliminary insights into the rea-
sons for restrictive syringe sales practices in Tijuana.
First, we found high levels of discordance between stated
pharmacy syringe sales practices and mystery shopper
outcomes. The fact that practices experienced by the
mystery shoppers were more restrictive than those stated
in the telephone survey suggests pharmacies are less
likely to sell syringes to suspected IDUs. Our mystery
shoppers were study staffers who, although not current
drug users, had a history of injection drug use and for the
purposes of the study dressed in a manner consistent
with IDUs in the area; it is thus reasonable to believe that
they were suspected of injection drug use. Further, seven
pharmacies in our telephone survey willingly stated that
their decision to request a prescription for syringe pur-
chase hinged on the appearance of the customer. IDUs in
Tijuana have spoken at length with us about the per-
ceived role of appearance in their attempts to purchase
syringes, and we have demonstrated an independent
association between homelessness - which influences the
ability of IDUs to maintain the cleanliness of their person
and clothing - and encountering barriers to syringe pur-
chase [14]. These findings indicate that suspecting a per-
son of injection drug use is a motivating factor for
pharmacy staff in denying syringe purchase in Tijuana.
U.S. studies have identified a number of reasons why
pharmacies deny syringes to suspected IDUs. These
include business considerations including worries regard-
ing store theft, the security of pharmacy staff and custo-
mers, and increased drug use and discarding of used
syringes near the pharmacy [26-34]. Individual attitudes
of pharmacy staff also play a role; these include negative
attitudes toward drug use and drug users, concerns that
distributing syringes increases drug use and the belief
that selling syringes is not appropriate for pharmacists in
their role as health care professionals [26,28,30,31,34].
Studies that incorporate interviews with pharmacy own-
ers, pharmacists and clerks in Tijuana are needed to
Table 2 Comparison of telephone survey and mystery shopper outcomes
Phone survey outcomes
Sells syringes Doesn’t sell syringes Total
Successful 39 (32.5) 3 (18.8) 42 (30.9)
Unsuccessful 81 (67.5) 13 (81.3) 94 (69.1)
Total 120 (88.2) 16 (11.8) 136 (100.0)
Mystery shopper outcomes
No prescription Requires prescription Total
No prescription 64 (86.5) 13 (59.1) 77 (70.6)
Requires prescription 10 (13.5) 22 (62.9) 32 (29.4)
Total 74 (67.9) 35 (32.1) 109* (100.0)
*11 of the 120 pharmacies that reported selling syringes in the telephone survey did not give a definitive answer regarding their prescription policies.
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determine whether these factors influence syringe sales
decisions and identify other factors amenable to interven-
tion. These studies constitute the next phase of our
research activities in Tijuana.
One of these other factors may be misunderstanding of
the laws regarding pharmacy syringe sales in Mexico.
Almost one-third of the pharmacies interviewed by tele-
phone said they require a prescription for syringe pur-
chase. It is possible that pharmacy management and staff
do not have an accurate understanding of the laws govern-
ing syringe sales in Mexico. Alternatively, it is possible
that, for reasons that remain unclear, they feel the need to
obtain a prescription despite what the law allows. In quali-
tative interviews with IDUs, they posited that pharmacies
fear retribution from police if they are caught selling syr-
inges to IDUs [14]. None of the pharmacies in this study
cited fear of police to the mystery shopper or telephone
interviewer, but prior studies in Tijuana by our research
team have found high rates of arrest for possession of ster-
ile syringes among IDUs, even though possession of these
syringes is allowed under Mexican law [35]. If fear of
police is indeed a factor in pharmacy syringe sales prac-
tices then police behavior would need to be targeted as
part of any pharmacy-based intervention.
Regardless of their reasons for requesting a prescription,
it is clear that pharmacies’ prescription policies are not
applied consistently. Our study found discordance
between pharmacy prescription policies reported in the
telephone survey and policies encountered by the mystery
shoppers at the same pharmacies. As expected, most of
these discrepancies went in one direction, with pharmacies
reporting not requiring a prescription but asking the mys-
tery shopper for one anyway. However, we also identified
pharmacies that sold syringes to the mystery shopper
despite a stated policy of requiring a prescription. Further,
our mystery shoppers reported encountering disagree-
ments among pharmacy staff regarding whether or not to
sell the shopper a syringe; these disagreements may
explain some of the discrepancies we encountered in com-
paring our mystery shopper and telephone survey findings,
as the outcome may have depended greatly upon which
pharmacy staffer waited on the mystery shopper or
answered the survey call. Interventions that seek to bring
pharmacies into compliance with Mexican laws allowing
over-the-counter syringe sales will need to ensure that
these policies are understood and implemented consis-
tently across the staff within each pharmacy.
Finally, the overall rate of successful purchases
achieved in this study was lower than the success rates
achieved by U.S.-based studies employing a similar
methodology [8-12]. Although our findings cannot be
extrapolated to other developing countries - or even to
other regions in Mexico - they raise the possibility that
access to sterile syringes through retail pharmacies in
developing countries where syringes are legally available
without a prescription may be more limited than in
developed countries with the same policies. This possi-
bility should be investigated by researchers in developing
countries where IDUs constitute a substantial propor-
tion of new HIV cases.
U.S.-based mystery shopper studies have documented
significant differences in outcomes depending on whether
a retail pharmacy is a chain or independent establishment.
Because we were not able to determine the chain/indepen-
dent status of several pharmacies while developing our vali-
dated pharmacy list, we did not include this variable in our
study. We also identified only a very small number of phar-
macies that attempted to overcharge the mystery shoppers
for syringes, which was inconsistent with our prior qualita-
tive findings that overcharging is common [13,14]. This
may be attributed to the fact that, for reasons of staffing
and safety, we did not conduct any purchase attempts after
6:00 pm. Given that IDUs have reported higher likelihood
of overcharging in the late evenings and early mornings,
our findings may underestimate the frequency of overchar-
ging. IDUs have also reported a higher likelihood of over-
charging when they appear to be in opiate withdrawal,
which our mystery shoppers clearly were not.
Conclusions
We documented a substantial difference between the
“laws on the books” that govern syringe sales in Mexico
and the actual sales practices of retail pharmacies in
Tijuana. A clearer understanding of what motivates
these sales practices is needed. Structural interventions
that build upon this knowledge should be prioritized
among public health efforts to expand syringe access
and reduce transmission of HIV and other blood-borne
pathogens among IDUs.
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